My Blue Dots

BRANFORD, Conn.–(BUSINESS WIRE)–Quantum-Si’s New Preprint Showcases Protein Barcoding as a Powerful Tool for Transforming Proteomics

SAN DIEGO & OXFORD, England–(BUSINESS WIRE)– #AploScope–ONI (Oxford Nanoimaging), a life science tools company focused on developing super-resolution microscopy, announced today the launch of the Aplo Scope, a single molecule super-resolution microscope that enables scientists to observe and measure molecular interactions within cells and tissues with unparalleled precision. The Aplo Scope addresses a critical challenge in single-molecule research—capturing the intricate details of biological systems in

BELOIT, Wis. & LAGUNA HILLS, Calif.–(BUSINESS WIRE)–NorthStar Medical Radioisotopes and YAP Therapeutics Enter into Collaboration Agreement for Development and Production of Radiopharmaceutical Products

BOSTON–(BUSINESS WIRE)–MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver transformative therapies to patients, today announced the promotion of Rami Rahal, Ph.D., to Partner. “We are proud to announce Rami’s well-deserved promotion in recognition of the tremendous value he has brought to the public investing team at MPM BioImpact,” said Christiana Bardon, M.D., Managing Partner of MPM BioImpact. “Our goal is to invest in companies

PEKÍN, ALAMEDA (California) y TAIPÉI–(BUSINESS WIRE)–Biocytogen (HKEX: 02315) y Acepodia (6976:TT) anunciaron hoy una alianza estratégica para evaluar de forma conjunta un programa de conjugados de anticuerpos-fármacos biespecíficos de carga doble (BsAD2C). Esta colaboración combina la plataforma RenLite® de Biocytogen con la tecnología de conjugación anticuerpo-fármaco doble (AD2C) de Acepodia para enfrentar algunos de los desafíos oncológicos más difíciles, como la heterogeneidad y la resis

SAN FRANCISCO–(BUSINESS WIRE)–Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome (CRS), maximum tolerated dose (MTD) not yet reached as dose escalation co

CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 5, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President &

BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 15,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have

NEWARK, Del.–(BUSINESS WIRE)– #CRISPR–CorriXR Therapeutics, Inc., a pioneering biotherapeutics company focused on oncology and innovative technologies to overcome drug resistance in solid tumors, announced that Jan Case has joined the Company as Chief Operating Officer. With over 25 years of experience in the biotechnology and pharmaceutical sectors, Case has driven operational excellence and strategic growth. As president of Cellicon Valley Consulting, she helped biotech start-ups, especially in the

BURLINGTON, Mass & NEW YORK–(BUSINESS WIRE)—- $BFLY #POCUS–Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”, “the Company”), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced that it expects to report revenue growth for the fourth quarter ended December 31, 2024 of approximately 35% year over year. Joseph DeVivo, Butterfly’s President, Chief Executive Officer and Chairman commented, “The Butterfly team closed out 2024